Opportunities and guidelines for discovery of orally absorbed drugs in beyond rule of 5 space

Vasanthanathan Poongavanam, Bradley C. Doak, Jan Kihlberg

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Recent years have seen a dramatic increase in the number of drugs approved in chemical space outside of Lipinski's rule of 5, that is in what has been termed beyond rule of 5 (bRo5) space. The development of three major classes of oral drugs that treat HIV and HCV infections and the growing evidence that novel, difficult targets can be accessed has prompted research into understanding design of drugs displaying cell permeability, solubility and ultimately oral bioavailability in bRo5 space. Studies have found a consistent outer property limit for a reasonable chance of de novo designing oral bioavailability. In addition, several property-based guidelines, along with incorporation of chameleonic features, have emerged as strategies to aid design in bRo5 space. A more detailed understanding of the complex and environment dependent conformational landscape will likely be the focus of the next generation of guidelines allowing property predictions of ever more complex compounds. By pushing the boundaries of current orally designable chemical space we hope that discoveries will be made for fundamental science and also for discovery of novel therapeutics.

Original languageEnglish
Pages (from-to)23-29
Number of pages7
JournalCurrent Opinion in Chemical Biology
Volume44
DOIs
Publication statusPublished - 1 Jun 2018

Cite this

@article{2e4ae7f36327471f8f6dc650c24950ab,
title = "Opportunities and guidelines for discovery of orally absorbed drugs in beyond rule of 5 space",
abstract = "Recent years have seen a dramatic increase in the number of drugs approved in chemical space outside of Lipinski's rule of 5, that is in what has been termed beyond rule of 5 (bRo5) space. The development of three major classes of oral drugs that treat HIV and HCV infections and the growing evidence that novel, difficult targets can be accessed has prompted research into understanding design of drugs displaying cell permeability, solubility and ultimately oral bioavailability in bRo5 space. Studies have found a consistent outer property limit for a reasonable chance of de novo designing oral bioavailability. In addition, several property-based guidelines, along with incorporation of chameleonic features, have emerged as strategies to aid design in bRo5 space. A more detailed understanding of the complex and environment dependent conformational landscape will likely be the focus of the next generation of guidelines allowing property predictions of ever more complex compounds. By pushing the boundaries of current orally designable chemical space we hope that discoveries will be made for fundamental science and also for discovery of novel therapeutics.",
author = "Vasanthanathan Poongavanam and Doak, {Bradley C.} and Jan Kihlberg",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/j.cbpa.2018.05.010",
language = "English",
volume = "44",
pages = "23--29",
journal = "Current Opinion in Chemical Biology",
issn = "1367-5931",
publisher = "Elsevier",

}

Opportunities and guidelines for discovery of orally absorbed drugs in beyond rule of 5 space. / Poongavanam, Vasanthanathan; Doak, Bradley C.; Kihlberg, Jan.

In: Current Opinion in Chemical Biology, Vol. 44, 01.06.2018, p. 23-29.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Opportunities and guidelines for discovery of orally absorbed drugs in beyond rule of 5 space

AU - Poongavanam, Vasanthanathan

AU - Doak, Bradley C.

AU - Kihlberg, Jan

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Recent years have seen a dramatic increase in the number of drugs approved in chemical space outside of Lipinski's rule of 5, that is in what has been termed beyond rule of 5 (bRo5) space. The development of three major classes of oral drugs that treat HIV and HCV infections and the growing evidence that novel, difficult targets can be accessed has prompted research into understanding design of drugs displaying cell permeability, solubility and ultimately oral bioavailability in bRo5 space. Studies have found a consistent outer property limit for a reasonable chance of de novo designing oral bioavailability. In addition, several property-based guidelines, along with incorporation of chameleonic features, have emerged as strategies to aid design in bRo5 space. A more detailed understanding of the complex and environment dependent conformational landscape will likely be the focus of the next generation of guidelines allowing property predictions of ever more complex compounds. By pushing the boundaries of current orally designable chemical space we hope that discoveries will be made for fundamental science and also for discovery of novel therapeutics.

AB - Recent years have seen a dramatic increase in the number of drugs approved in chemical space outside of Lipinski's rule of 5, that is in what has been termed beyond rule of 5 (bRo5) space. The development of three major classes of oral drugs that treat HIV and HCV infections and the growing evidence that novel, difficult targets can be accessed has prompted research into understanding design of drugs displaying cell permeability, solubility and ultimately oral bioavailability in bRo5 space. Studies have found a consistent outer property limit for a reasonable chance of de novo designing oral bioavailability. In addition, several property-based guidelines, along with incorporation of chameleonic features, have emerged as strategies to aid design in bRo5 space. A more detailed understanding of the complex and environment dependent conformational landscape will likely be the focus of the next generation of guidelines allowing property predictions of ever more complex compounds. By pushing the boundaries of current orally designable chemical space we hope that discoveries will be made for fundamental science and also for discovery of novel therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=85047384224&partnerID=8YFLogxK

U2 - 10.1016/j.cbpa.2018.05.010

DO - 10.1016/j.cbpa.2018.05.010

M3 - Review Article

VL - 44

SP - 23

EP - 29

JO - Current Opinion in Chemical Biology

JF - Current Opinion in Chemical Biology

SN - 1367-5931

ER -